Zacks Investment Research upgraded shares of IntelGenx Technologies Corp. (NASDAQ:IGXT) from a sell rating to a hold rating in a research note published on Wednesday, July 12th.

According to Zacks, “IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company’s research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. “

COPYRIGHT VIOLATION NOTICE: “IntelGenx Technologies Corp. (NASDAQ:IGXT) Raised to Hold at Zacks Investment Research” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/07/intelgenx-technologies-corp-nasdaqigxt-upgraded-to-hold-at-zacks-investment-research-updated-updated-updated.html.

Get a free copy of the Zacks research report on IntelGenx Technologies Corp. (IGXT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for IntelGenx Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies Corp. and related stocks with our FREE daily email newsletter.